NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it has signed an agreement to develop and commercialize a next-generation sequencing-based companion diagnostic for Agios Pharmaceuticals' investigational cancer drug ivosidenib.

Ivosidenib is an inhibitor of isocitrate dehydrogenase 1 (IDH1), which is mutated in various cancers. It is currently in Phase III testing in patients with cholangiocarcinoma — a rare cancer of the bile duct system — who harbor IDH1 mutations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.